# PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the "Code")

#### 1. KEY INFORMATION

(a) Full name of discloser:	Premier Veterinary Group plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and	N/A
beneficiaries must be named.  (c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Premier Veterinary Group plc
(d) Is the discloser the offeror or the offeree?	OFFEREE
(e) Date position held:  The latest practicable date prior to the disclosure	28 September 2023
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?  If it is a cash offer or possible cash offer, state "N/A"	N/A

### 2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

## (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:				
	Interests		Short position	ons
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	Nil		Nil	
(2) Cash-settled derivatives:	Nil		Nil	
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	Nil		Nil	
TOTAL:	Nil		Nil	

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

### (b) Rights to subscribe for new securities

Class of relevant security in relation to	None
which subscription right exists:	
Details, including nature of the rights	None
concerned and relevant percentages:	

## 3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

(a) Interests in Premier Veterinary Group plc's ordinary shares in which the directors of Premier Veterinary Group plc are interested (including their close relatives and related trusts):

Director	Number of ordinary shares (0.1p)	Percentage of issued share capital <sup>1</sup>
Rajan Uppal <sup>2,3,4</sup>	6,369,454	38.60%
Dominic Tonner <sup>2,4</sup>	2,071,874	12.55%
Andy Paull <sup>2</sup>	56,500	0.34%
Neil Wood <sup>2</sup>	2,606	0.01%

- 1. Based on issued share capital of 16,497,970 (and excludes the ordinary A shares detailed below)
- 2. Includes shares held by family members
- 3. Includes shares held in the Rajan Uppal 2022 Trust
- 4. Bybrook Financial Solutions Limited (whose sole shareholder and director is Rajan Uppal) ("BFSL") and Crossroads Finance Limited (a company wholly owned by Dominic Tonner and his wife) ("Crossroads"), Rajan Uppal, Tracey Uppal (wife of Rajan Uppal) and Dominic Tonner and all of the direct and indirect subsidiaries of BFSL and Crossroads and any associated companies and companies of which such companies are associated companies are defined as acting in concert. Together they hold 8,441,328 ordinary shares.
- (b) Interests in Premier Veterinary Group plc's ordinary A shares in which the directors of Premier Veterinary Group plc are interested (including their close relatives and related trusts):

Director	Number of ordinary A shares (0.1p)	Percentage of issued share capital including ordinary A shares <sup>1</sup>
Dominic Tonner	645,269 <sup>2</sup>	100.00%

- 1. Based on issued ordinary A share capital of 645,269
- Ordinary A Shares are subject to automatic conversion into, and re-designation as, A
  deferred shares of £0.10 nominal value each ("A Deferred Shares") on the basis of
  one A Deferred Share for every A Share in the event of a sale
- (c) Options over Premier Veterinary Group plc's ordinary shares held by the directors of Premier Veterinary Group plc and their close relatives and related trusts:

Name	Option	Date of	Number	Exercise	Vesting	Expiry
	scheme	award	of shares	price	date	date

Dominio	2014 EMI	27	270 025	CO 1010	27	27
Dominic	2014 EMI	27	279,035	£0.1010	27	27
Tonner	Scheme	February			February	February
		2015			2016	2025
Employees	2014 EMI	13	94,517	£0.4617	13	13
	Scheme	February			February	February
		2019			2022	2029
Employees	2014 EMI	13	45,000	£0.4617	13	13
	Scheme -	February			February	February
	Unapproved	2019			2022	2029
Employees	2020 EMI	2 March	1,120,094	£0.5000	2 March	12
	Scheme	2021			2021	October
						2025
Dominic	2020 EMI	2 March	633,094	£0.5000	2 March	12
Tonner	Scheme	2021			2021	October
						2025
Andy Paull	2020 EMI	2 March	486,996	£0.5000	2 March	12
-	Scheme	2021			2021	October
						2025
Employees	2020 EMI	2 March	340,894	£0.5000	2 March	12
	Scheme –	2021			2021	October
	Unapproved					2025
	Unapproved				2021	

## (d) Convertible loans over Premier Veterinary Group plc's ordinary shares held:

Name	Date of award	Number of shares	Exercise price	Exercise period / vesting date
Denplan Limited	12 October 2020	15,346,949	£0.1000	The earlier of a sale of the Company, a listing of the Company, a sale of all or a material part of the business and assets of the Company and 12 October 2025

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

### 4. OTHER INFORMATION

## (a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None

## (b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

- (i) the voting rights of any relevant securities under any option; or
- (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

### (c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	NO
Supplemental Form 8 (SBL)	NO

Date of disclosure:	29 September 2023
Contact name:	Andy Paull, Chief Finance Officer
Telephone number:	+44 117 370 0300

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.